

No.18-95

November 8, 2018  
Eisai Co., Ltd.

**EISAI COMMENCES FULL-SCALE OPERATION OF  
NEW SUZHOU PLANT IN CHINA**  
*STRENGTHENS IN-HOUSE DOMESTIC PRODUCTION SYSTEM IN CHINA*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.



(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)

Aiming to further expand its contribution to patients in China, Eisai has been working to establish the new Suzhou plant as the plant with the largest production capacity under the Eisai Group on a new industrial site more than five times larger than the former Suzhou plant (oral solid dose production facility scheduled for closure at the end of November 2018) at approximately 134,000m<sup>2</sup> in size to further strengthen the stable supply chain as well as improve production efficiency. The new Suzhou plant's oral solid dose production facility has a production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) which is approximately double that of the former Suzhou plant, and handles the formulation and packaging of oral solid dose products such as Methycobal®, Aricept® and Pariet® for the domestic Chinese market. In addition, ECI established a parenteral facility (production capacity: 60 million bottles per year) in advance in November 2014, where it manufactures the injection formulation of Methycobal.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. With the full-scale commencement of operations at the new Suzhou plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

**[Notes to editors]**

**1. Outline of New Suzhou Plant**

Location: 168 Xingpu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China

Site area: Approximately 134,000 m<sup>2</sup>



(Bird's eye view of the new Suzhou plant)

(1) Oral Solid Dose Production Facility

- Floor space: Approximately 20,240 m<sup>2</sup> / Three floors
- Main functions: Formulation, packaging, storage, etc.
- Products to be manufactured: Methycobal, Aricept, Pariet and other products

(2) Parenteral Production Facility

- Floor space: Approximately 5,690 m<sup>2</sup> / Two floors
- Products manufactured: Methycobal injection and other products

(3) Administration Building

- Floor space: Approximately 2,230 m<sup>2</sup> / Two floors
- Main facilities: Offices, meeting rooms, cafeteria, etc.

(4) Distribution Warehouse

- Floor space: Approximately 7,812 m<sup>2</sup> / One floor